Detailed Information on Publication Record
2012
Lenalidomide: a new treatment option for Castleman disease
SZTURZ, Petr, Zdeněk ADAM, Jana CHOVANCOVÁ, Olga STEHLÍKOVÁ, Martin KLABUSAY et. al.Basic information
Original name
Lenalidomide: a new treatment option for Castleman disease
Authors
SZTURZ, Petr (203 Czech Republic, belonging to the institution), Zdeněk ADAM (203 Czech Republic, guarantor, belonging to the institution), Jana CHOVANCOVÁ (203 Czech Republic, belonging to the institution), Olga STEHLÍKOVÁ (203 Czech Republic, belonging to the institution), Martin KLABUSAY (203 Czech Republic, belonging to the institution), Z. ŘEHÁK (203 Czech Republic), R. KOUKALOVÁ (203 Czech Republic), Lenka ZAHRADOVÁ (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)
Edition
Leukemia & Lymphoma, LONDON, INFORMA HEALTHCARE, 2012, 1042-8194
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.301
RIV identification code
RIV/00216224:14110/12:00060973
Organization unit
Faculty of Medicine
UT WoS
000308213400024
Keywords in English
Lenalidomide; Castleman disease
Tags
International impact
Změněno: 28/11/2012 14:22, Mgr. Michal Petr
Abstract
V originále
A male born in 1961, aged 46, was referred to our department for evaluation of splenomegaly and generalized lymphadenopathy aff ecting the cervical, axillary, mediastinal, retroperitoneal and inguinal regions. Laboratory data revealed an increased erythrocyte sedimentation rate (16 mm/h and 30 mm/2 h) and C-reactive protein level (35.4 mg/L). Total protein and full blood counts as well as renal and hepatic profi les were within normal ranges, and microbiological screening revealed no infectious etiology. Other fi ndings, including radiological examinations and bone marrow biopsy, showed no further pathologies. Th e patient ’ s other medical history was signifi cant for arterial hypertension, chronic infl ammatory demyelinating polyneuropathy and mild right hemi-paresis with expressive language disorder. Based on lymph node biopsies from retroperitoneal and both inguinal regions, the patient was diagnosed with the plasma-cell variant of CD. Th e presence of a large pelvic mass compressing adjacent structures indicated the patient for therapy initiation. During fi rst-line treatment (R-CHOP: rituximab 375 mg/m 2 , cyclophosphamide 750 mg/m 2 , doxorubicin 50 mg/m 2 and vincristine 2 mg intravenously on day 1; prednisone 100 mg perorally on days 1 – 5 in a 21-day cycle, three cycles in total, 12/2008 – 2/2009), clinical progression of the disease was evident (gastrointestinal symptoms, swollen hands and feet with signs of vasculitis), and there was no radiological response on a restaging computed tomography (CT) examination after 3 months.
Links
| LC06027, research and development project |
| ||
| MSM0021622434, plan (intention) |
| ||
| NS9671, research and development project |
| ||
| NT11154, research and development project |
|